Home > Result Summaries: Compounds > Combined Measles, Mumps, Rubella, Varicella Vaccine > Result Summary for 208136/013

Result Summary for 208136/013

Result Summary

Protocol ID:	208136/013
Clinical Study ID:	208136/013 (MeMuRu-OKA-013)
Official Title:	Study to assess immunogenicity and safety of one dose of GSK Bios’ live attenuated MMRV vaccine, co-admind with a booster dose of the GSK Bios’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine
Phase:	Phase 3
Study Indications or Diseases:	Measles-Mumps-Rubella-Varicella Vaccine
Generic Name:	Combined Measles, Mumps, Rubella, Varicella Vaccine
Trade/Product Name:	Priorix-Tetra;Priorix-Tetra
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Knuf M et al. (2008) A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc). 44(4):279-292. Zepp F et al. (2007) Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr. 166 (8):857-864. Sohita D et al. (2008) Live Attenuated Measles, Mumps, Rubella, and Varicella Zoster Virus Vaccine (Priorix-Tetra). Pediatric Drugs. 10(5): 337-347.